144 related articles for article (PubMed ID: 25554010)
1. National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009.
Mahal BA; Hoffman KE; Efstathiou JA; Nguyen PL
Clin Genitourin Cancer; 2015 Jun; 13(3):e167-72. PubMed ID: 25554010
[TBL] [Abstract][Full Text] [Related]
2. Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results Medicare analysis.
Sheets NC; Hendrix LH; Allen IM; Chen RC
Cancer; 2013 Sep; 119(18):3295-301. PubMed ID: 23842985
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy use with post-prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria.
Ong WL; Foroudi F; Evans S; Millar J
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):124-130. PubMed ID: 30295411
[TBL] [Abstract][Full Text] [Related]
4. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center.
Martin JM; Li T; Johnson ME; Murphy CT; Howald AG; Smaldone MC; Kutikov A; Chen DY; Viterbo R; Greenberg RE; Uzzo RG; Horwitz EM
J Natl Compr Canc Netw; 2015 May; 13(5):525-30. PubMed ID: 25964638
[TBL] [Abstract][Full Text] [Related]
5. Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.
Wang K; Sheets NC; Basak R; Chen RC
Cancer; 2016 Oct; 122(19):3069-74. PubMed ID: 27352280
[TBL] [Abstract][Full Text] [Related]
6. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
7. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant radiotherapy after radical prostatectomy: indications, results and side effects.
Bottke D; Wiegel T
Urol Int; 2007; 78(3):193-7. PubMed ID: 17406125
[TBL] [Abstract][Full Text] [Related]
11. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.
Leibovich BC; Engen DE; Patterson DE; Pisansky TM; Alexander EE; Blute ML; Bergstralh EJ; Zincke H
J Urol; 2000 Apr; 163(4):1178-82. PubMed ID: 10737490
[TBL] [Abstract][Full Text] [Related]
12. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
13. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
14. Knowledge, attitudes and beliefs towards management of men with locally advanced prostate cancer following radical prostatectomy: an Australian survey of urologists.
Brown B; Young J; Kneebone AB; Brooks AJ; Dominello A; Haines M
BJU Int; 2016 Apr; 117 Suppl 4():35-44. PubMed ID: 25585989
[TBL] [Abstract][Full Text] [Related]
15. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression].
Bolla M; Van Poppel H; Collette L;
Cancer Radiother; 2007 Nov; 11(6-7):363-9. PubMed ID: 17931949
[TBL] [Abstract][Full Text] [Related]
17. Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria.
Gandaglia G; Karakiewicz PI; Briganti A; Trudeau V; Trinh QD; Kim SP; Montorsi F; Nguyen PL; Abdollah F; Sun M
Int J Urol; 2015 Jan; 22(1):89-95. PubMed ID: 25141965
[TBL] [Abstract][Full Text] [Related]
18. Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty.
Kim SP; Tilburt JC; Karnes RJ; Ziegenfuss JY; Han LC; Shah ND; Frank I; Smaldone MC; Gross CP; Yu JB; Trinh QD; Sun M; O'Malley RL; Nguyen PL
Urology; 2013 Oct; 82(4):807-12. PubMed ID: 23910088
[TBL] [Abstract][Full Text] [Related]
19. Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy.
Rose BS; Chen MH; Zhang D; Hirsch MS; Richie JP; Chang SL; Hegde JV; Loffredo MJ; D'Amico AV
Clin Genitourin Cancer; 2014 Oct; 12(5):e173-9. PubMed ID: 24787967
[TBL] [Abstract][Full Text] [Related]
20. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.
Van der Kwast TH; Bolla M; Van Poppel H; Van Cangh P; Vekemans K; Da Pozzo L; Bosset JF; Kurth KH; Schröder FH; Collette L;
J Clin Oncol; 2007 Sep; 25(27):4178-86. PubMed ID: 17878474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
